-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $38

Benzinga·08/06/2026 13:28:18
Listen to the news
Guggenheim analyst Seamus Fernandez maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $35 to $38.